Drug Database
EB

Ebola vaccine (Mvabea)

✓ Approved

Johnson & Johnson Services, Inc. · Recombinant Proteins · Recombinant Proteins

What is Ebola vaccine?

Ebola vaccine is a recombinant proteins developed by Johnson & Johnson Services, Inc.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesMvabea
CompanyJohnson & Johnson Services, Inc.
Drug ClassRecombinant Proteins, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Johnson & Johnson Services, Inc.

Therapeutic Indications

Ebola vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersCongenital Ebola virus infection✓ Approved

Related Research Articles

PubMedCureus2026-05-25

Provincial Trends in Childhood Vaccine Coverage in Afghanistan From 2000 to 2024: An Ecological Study of Findings From the Institute for Health Metrics and Evaluation.

Khan Ahmad A, Tidman Melanie M

This study analyzes vaccination coverage trends across 34 provinces in Afghanistan from 2000 to 2024, using data from the Institute for Health Metrics and Evaluation (IHME). Coverage rates for bacillus Calmette-Guérin (BCG), diphtheria-tetanus-pertussis third dose (DTP3), measles-containing vaccine first dose (MCV1), polio vaccine (three doses), pneumococcal conjugate vaccine third dose (PCV3), hepatitis B vaccine third dose (HepB3), Haemophilus influenzae type b vaccine third dose (Hib3), and rotavirus vaccine (RotaC) were assessed using the Kruskal-Wallis and Friedman tests. The Friedman test and Kruskal-Wallis H test were used to assess significant differences in vaccination coverage trends across the 34 provinces in Afghanistan from 2000 to 2024, enabling a comprehensive analysis of provincial and temporal trends. A downward trend in vaccination coverage was observed during the COVID-19 pandemic and after international aid limitations following the political change that occurred in Afghanistan in 2021. This decline in coverage may be associated with disruptions in vaccine distribution during these critical periods. Besides individual factors, vaccination adherence is influenced by health system factors, including vaccine availability and accessibility. The results of the Kruskal-Wallis and Friedman tests showed significant variability in vaccination coverage trends across the 34 provinces from 2000 to 2024. These findings highlight the need for intensive efforts to improve vaccination coverage in all 34 provinces to protect those most at risk.

PMID 42182556
Read full article →
PubMedFrontiers in pharmacology2026-05-25

Artificial intelligence for coordinating vaccine design, antiviral discovery, and real-world monitoring in the era of emerging and endemic viral threats.

Akingbola Adewunmi A, Adegbesan Abiodun A, Adewole Olajumoke O, Adebiyi Kehinde O KO et al.

Vaccine development has traditionally been a lengthy and resource-intensive process, often struggling to keep pace with rapidly emerging infectious threats. Recent advances in artificial intelligence (AI) offer new opportunities to transform this landscape by enabling faster, more precise, and data-driven approaches to vaccine design. This review examines how AI is being applied across key stages of vaccine development, including antigen discovery, epitope prediction, structural optimisation, immunogenicity assessment, and safety evaluation. We highlight the use of machine learning and deep learning models to analyse large-scale genomic, proteomic, and immunological datasets, allowing for more targeted identification of promising vaccine candidates. While AI-driven approaches show considerable promise, their successful translation into effective vaccines depends on the quality and representativeness of the data used, as well as close integration with experimental and clinical validation. Current challenges include data bias, limited representation of populations from low- and middle-income countries, and the need for transparent and interpretable models that can support regulatory decision-making. By synthesising recent developments and ongoing challenges, this review underscores the potential of AI to complement traditional vaccine development pipelines. When responsibly implemented, AI-based methods may accelerate vaccine innovation, improve global preparedness, and support more equitable responses to future infectious disease outbreaks.

PMID 42181885
Read full article →
PubMedbioRxiv : the preprint server for biology2026-05-25

Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.

Kumar Sanjeev S, Lai Lilin L, Ellis Madison L ML, Patel Anamika A et al.

The emergence of the SARS-CoV-2 Omicron BA.2.86 subvariant, a lineage derived from the BA.2 strain, led to the 2024-2025 COVID-19 vaccine update to include KP.2 or related JN.1-lineage spike antigens. We evaluated the magnitude, breadth, and durability of humoral immune responses following a single KP.2 vaccine dose in a longitudinal cohort of 21 individuals up to six months. KP.2 vaccination increased spike-specific binding and neutralizing antibodies against the ancestral WA1 strain, alongside the BA.5, XBB.1.5, and KP.2 variants. Power law modeling estimated half-lives for WA1- and KP.2-specific IgG responses at 770 and 248 days, respectively. Additionally, the KP.2 dose increased IgG1 and IgG4 subclasses more than IgG2 and IgG3 responses to both spike proteins. Serum depletion experiments using WA1 or KP.2 proteins demonstrated most vaccine-elicited antibodies were cross-reactive. Consequently, KP.2 vaccine-induced antibodies retained broad neutralizing activity against recently circulating Omicron subvariants (BA.2.86, KP.3.1.1, XEC, LP.8.1, LF.7, XFG.3.12, PQ.1, BA.3.2.1, and RE.2). Using a live virus neutralization assay, XFG.3.12 showed the greatest reduction in neutralizing titers relative to KP.2 (4.2-fold). In a small subset, an LP.8.1 vaccine dose increased neutralizing activity against the matched variant while maintaining WA1 and KP.2 cross-reactivity, but only modestly increased antibodies to divergent variants BA.3.2.1 and RE.2. Ultimately, these data indicate the KP.2 mRNA vaccine generates durable, cross-reactive responses against current Omicron subvariants. However, ongoing spike evolution impacts neutralization of emerging lineages, highlighting the need for continued viral monitoring and timely vaccine updates. SARS-CoV-2 continues to evolve, raising ongoing concerns about how well updated vaccines protect against emerging variants. This study evaluates antibody responses after KP.2 spike mRNA vaccine dose and shows that a single dose induces durable and broadly cross-reactive immunity against both earlier strains and recently circulating Omicron subvariants. Despite this breadth, reduced neutralizing activity against certain emerging variants indicates that ongoing antigenic changes can impact vaccine induced antibody effectiveness. These findings provide insight into how current vaccines perform over time and highlight the need to track viral evolution and update vaccine antigens to maintain broad protection against severe disease, hospitalization, and death.

PMID 42182132
Read full article →
PubMedFrontiers in health services2026-05-25

Examining perceptions, social, and policy factors influencing hepatitis B birth-dose vaccine uptake: a PEN-3 cultural model mixed-methods study of healthcare workers in Nigeria.

Olusanya Olufunto A OA, Adedeji Oluwakorede O, Ngoe Caven C, Oladele David D et al.

The timely administration of the birth-dose hepatitis B (HepB-BD) vaccine is recommended by global and national guidelines to effectively prevent perinatal transmission. In high-disease-burden countries, such as Nigeria, the adoption of the HepB-BD vaccine remains limited. Emerging global policy discussions highlight the need to examine healthcare workers' (HCWs') perceptions of pediatric vaccination guidelines, the safety and effectiveness of the HepB-BD vaccine, and how family, social support, and community factors influence vaccine delivery. A convergent mixed-methods study of HCWs was conducted in Nigeria between July and August 2024. Using the PEN-3 Cultural Model as our framework, we concurrently administered quantitative surveys and conducted in-depth qualitative interviews and focus group discussions to assess knowledge, beliefs, and peer influences related to HepB-BD vaccinations. We also explored HCWs' perceptions, enabling factors, and social influences that impact vaccine delivery. Data were analyzed using descriptive statistics and thematic analysis. Most participants were women (87.8%), nurses (24.4%), and community extension workers (14.6%), with an average age of 32.5 years. Over half perceived HepB-BD vaccines as extremely safe (61%) and effective (63.4%). Participants strongly agreed that birth vaccination is recommended (80.5%), ethically appropriate (68.3%), and that its benefits outweigh side effects (63.4%). Most respondents reported professional autonomy in birth-dose decisions: 51.2% strongly disagreed that family opinions influenced their decisions, and 48.8% strongly disagreed that family/friends were concerned about their administering the vaccine. Qualitative themes included perceptions of barriers (poor knowledge, limited vaccine stock, misinformation), enablers (transportation and cold chain reliability), and nurturing factors (the role of training and collaboration with traditional birth attendants). Misconceptions included linking vaccines to sexually transmitted infections and concerns about fragile newborn immunity. HepB-BD vaccine delivery by HCWs is influenced by a complex interplay of multiple factors, including perceptions, structural enablers, and social relationships. As global policies continue to evolve, programs should adopt culturally responsive, context-specific strategies to address these multi-level influences and foster HCW trust, thereby ensuring the timely delivery of the HepB-BD vaccine.

PMID 42180634
Read full article →
PubMedSexually transmitted diseases2026-05-25

Temporal trends in anal HPV infection among men who have sex with men attending sexual health clinics in three United States cities, 2018-2024.

DeSisto Carla L CL, Querec Troy D TD, Winer Rachel L RL, Pathela Preeti P et al.

We assessed temporal trends in prevalent anal human papillomavirus (HPV) infection among men who have sex with men (MSM) without HIV who attended sexual health clinics in three U.S. cities during 2018-2024. Residual anal specimens from MSM without HIV, aged 18-45 years, were tested for 28 HPV genotypes. Demographic information was obtained from clinic records. Trends in quadrivalent vaccine (4vHPV)-type prevalence and non-vaccine-type HPV prevalence were evaluated using Joinpoint regression, stratified by age group (18-26 and 27-45 years). Non-vaccine-type HPV prevalence was used as a measure of sexual exposure; these HPV types are not targeted by any available vaccine. Joinpoint regression fits a series of joined straight lines on a logarithmic scale to the trends in prevalence; trends were reported as annual percent change (APC). Among persons aged 18-26 years, 4vHPV-type prevalence declined from 23.7% in 2018-2019 to 13.4% in 2023-2024 (APC = -13.4%), while non-vaccine-type HPV prevalence had a slight but non-significant decline. Among persons aged 27-45 years, 4vHPV-type prevalence declined from 37.2% in 2018-2019 to 28.2% in 2023-2024 (APC = -5.6%), while non-vaccine-type HPV prevalence remained stable. Among MSM aged 18-26 and 27-45 years, there was a decline in 4vHPV-type prevalent anal infections during 2018-2024. There was little to no decline in non-vaccine-type HPV prevalence during the same time period, suggestive of unchanging sexual exposure to HPV. These data demonstrate the impact of HPV vaccine on anal HPV infections in MSM.Summary: During 2018-2024, vaccine-type anal HPV infection declined by 13.4% and 5.6% annually among 18-26-year-old and 27-45-year-old men who have sex with men, respectively.

PMID 42183680
Read full article →
PubMedFrontiers in public health2026-05-25

Reducing parents' vaccination hesitancy: a new educational training model in Turkish sample.

Tümsek Gizem Solmaz GS, Akmeşe Zehra Baykal ZB

This study aimed to evaluate the effect of the New Education Model (NETM) on vaccine hesitancy among parents of infants hospitalized in a Neonatal Intensive Care Unit (NICU). This study was conducted using a one-group pretest-posttest quasi-experimental design. The intervention consisted of a structured, two-hour NETM program delivered through interactive sessions. Data were collected using the Personal Information Form (PIF) and the Vaccine Opposition Scale (VOS). Following the NETM intervention, a statistically significant decrease was observed in mean VOS scores from pre-test to post-test (p < 0.001). Significant improvements were also identified across all subscales, including reductions in attitudes legitimizing vaccine hesitancy, strategies to avoid vaccination, and overall hesitancy levels. The findings suggest that the NETM intervention is associated with improvements in vaccine-related attitudes among parents in the NICU setting. The NETM represents a structured and feasible educational approach that may support healthcare professionals, particularly nurses and midwives, in addressing vaccine hesitancy through individualized and interactive communication strategies.

PMID 42180446
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Ebola vaccine